Therapeutic Response

BRAF p.V600K status confers therapeutic sensitivity to Tovorafenib in patients with Low-Grade Glioma, NOS.

Statements

Source and description

Ojemda (tovorafenib) [package insert]. FDA. The U.S. Food and Drug Administration granted accelerated approval to tovorafenib for the treatment of patients 6 months of age and older with relapsed or refractory pediatric low-grade glioma (LGG) harboring a BRAF fusion or rearrangement, or BRAF V600 mutation. The product label states that this indication is approved under accelerated approval based on response rate and duration of response and furthermore that continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial(s).